The optimal treatment for intermediate-risk pulmonary embolism (PE) remains unclear. Our goal was to describe the safety and efficacy of the EkoSonic ultrasound-assisted catheter-directed thrombolysis system (EKOS Corporation, Bothell, Washington) in a real-world registry of patients with intermediate-risk PE. Fifty-three consecutive patients with intermediate-risk PE treated with ultrasound-assisted catheter-directed thrombolysis at Brigham and Women's Hospital from 2010 to 2014 were analyzed. The primary outcome was a change in directly measured pulmonary artery pressures as assessed using logistic regression with generalized estimating equations to account for serial measurements. Patients received an average of 24.6 ± 9 mg of alteplase using the EKOS catheter with an average treatment time of 15.9 ± 3 hours. After treatment, there was a 7.2- and a 11.4-mm Hg reduction in mean and systolic pulmonary artery pressure (95% confidence interval 4.7 to 9.7 mm Hg, p <0.001, and 95% confidence interval 7.8 to 15.0 mm Hg, p <0.001), respectively. In this cohort, 9.4% had any bleeding complication noted during their hospital stay. One patient's alteplase was prematurely discontinued for access site bleeding although no other interventions were required related to bleeding complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2014.12.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of ultrasound-assisted thrombolysis and mechanical thrombectomy in intermediate-high-risk pulmonary embolism.
Vasa
January 2025
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Essen, Germany.
Pulmonary embolism (PE) can result in high mortality. Early risk stratification and treatment are critical for individualized management. In patients with intermediate-high-risk (IHR) PE, guidelines recommend to consider a percutaneous catheter-directed treatment (CDT).
View Article and Find Full Text PDFImpact of kidney disease in patients undergoing catheter directed interventions for intermediate to high-risk pulmonary embolism.
Am J Med Sci
January 2025
Department of Medicine, Louisiana State University Health Science Center, Shreveport, LA, USA; Department of Cardiovascular sciences, Louisiana State University Health Science Center at Shreveport, Shreveport, LA, USA.
Background: Catheter-directed interventions (CDIs) for pulmonary embolism (PE) continue to evolve. However, due to the paucity of data, their use has been limited in patients with underlying kidney disease.
Methods: The National Readmission Database (2016-2020) was utilized to identify intermediate to high-risk PE (IHR-PE) patients requiring CDI (thrombectomy, thrombolysis, and ultrasound-assisted thrombolysis).
Research progress in interventional therapy for acute intermediate-high-risk and high-risk pulmonary embolism.
J Thorac Dis
November 2024
Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- Acute pulmonary embolism (APE) has a high mortality rate, particularly due to right heart failure in intermediate to high-risk patients, with current guidelines advocating for thrombolytic therapy in high-risk cases.
- Despite the recommendations, thrombolytic therapy is not commonly used due to risks like intracranial hemorrhage, and there's still uncertainty about the best treatment for intermediate-risk patients.
- New endovascular interventions, such as various types of thrombolysis and mechanical thrombectomy, show promise in improving heart function and reducing bleeding risks, prompting future research to better identify patients who would benefit from these treatments and enhance long-term outcomes.
Novel Challenges and Therapeutic Options for Pulmonary Embolism and Deep Vein Thrombosis.
J Pers Med
August 2024
Cardiology Division, Sant'Andrea Hostpital, 13100 Vercelli, Italy.
Acute pulmonary embolism (PE), often resulting from deep vein thrombosis (DVT), is the third most frequent cause of cardiovascular death and is associated with increasing incidence, causing considerable morbidity and mortality. This review aims to evaluate the efficacy, safety, and outcomes of treatment options in the management of acute PE and DVT, encompassing both established and emerging technologies, such as catheter-directed thrombolysis, aspiration thrombectomy, and other endovascular techniques. A comprehensive literature review was conducted, assessing clinical studies, trials, and case reports that detail the use of percutaneous interventions for PE and DVT and analyzing the advantages and disadvantages of each percutaneous system.
View Article and Find Full Text PDFUltrasound-Assisted Versus Standard Catheter-Directed Thrombolysis for Acute Pulmonary Embolism: Insights From National Inpatient Sample.
J Soc Cardiovasc Angiogr Interv
May 2024
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky.
Background: Pulmonary embolism is one of the leading causes of morbidity and mortality in the United States. Catheter-directed therapies have emerged as a promising treatment for managing intermediate- and high-risk patients; however, data comparing standard catheter-directed thrombolysis (SCDT) and ultrasound-assisted thrombolysis (USAT) are limited. This study aimed to investigate trends, outcomes, and predictors of mortality of both modalities from a nationally representative sample.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!